Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Antigen Express, a wholly-owned immunotherapeutic vaccines subsidiary of Generex Biotechnology, has received a notice of allowance from the US Patent Office relating to an application making augmentative pharmaceutical composition claims for the AE37 immunotherapeutic cancer vaccine.
Subscribe to our email newsletter
AE37 is currently under a randomized and controlled Phase II efficacy study in patients treated for breast cancer who are at high risk of recurrence.
Favorable results from this study have been reported previously.
Antigen Express has previously received allowances of broad claims surrounding its Ii-Key hybrid technology, which was used in the design of the AE37 vaccine platform.
The current allowance strengthens independent composition of matter claims directed to the AE37 peptide.
The full term of the new patent will extend through 5 January 2028.
Generex is engaged in the research, development and commercialization of drug delivery systems and technologies.
Generex’s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company’s proprietary RapidMist device.
The company’s buccal insulin spray product, Generex Oral-lyn is in Phase III clinical trials at several sites around the world.